|
| Nick S. R. Lan 2020 | Subodh Verma 2019 | ||
|
| Empagliflozin | Placebo | Empagliflozin | Placebo |
| Age (years) | 60.8 ± 9.5 | 65.1 ± 10.4 | 64 | 64 |
| Male gender | 19 (86.4) | 15 (68.2) | 44 (90) | 46 (96) |
| Duration of T2DM, median (IQR), y | 5.5 (4~12.25) | 8 (4~19.5) | 10.0 (4.0, 15.0) | 10.0 (5.0, 15.0) |
| NT-pro BNP, pg/mL | 297 (128~1497.5) | 262.5 (122~806) | 97 (46, 188) | 116 (62, 227) |
| medications | ||||
| ACE inhibitor | 22 (100) | 21 (95.5) | 40 (82) | 41 (85) |